

- Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

IC13 Rec'd PCT/PTO 29 MAR 2002

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2002 (use as many sheets as necessary)		Application Number	Unassigned 101089,501
		Filing Date	03/29/2002
		First Name of Inventor	Hiroyuki SAITO
		Group Art Unit	Unassigned 1636
		Examiner Name	Unassigned M. Burkhardt
Sheet 1 of 1	Attorney Docket Number	053466-0325	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MB	A1	5,346,991		ROY et al.	09/13/1994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	IL	83411		GENENTECH, INC.	07/31/1998		
MB	A3	WO	88/09817	✓	NEMERSON et al.	12/15/1988		
MB	A4	WO	88/07543	✓	EDGINGTON et al.	10/06/1988		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
MB	A5	RANDOLPH, G. et al. "Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and Trafficking Through Endothelium In Vitro," <i>Blood</i> (December 1, 1998), Vol. 92, No. 11, pp. 4167-4177.		
	A6	GIESEN, P. et al. "Blood-borne tissue factor: Another view of thrombosis," <i>Proc. Natl. Acad. Sci.</i> (March 1999), Vol. 96, pp. 2311-2315.		
	A7	NAKAYAMA, T. et al., (1999) Vol. 39, No. 4, 298-302.		
	A8	DRAKE, T. et al. "Functional Tissue Factor Is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line," <i>The Journal of Cell Biology</i> (July 1989), Vol. 109, pp. 389-395, The Rockefeller University Press.		
	A9	RAN, S. et al. "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature," <i>Cancer Research</i> (October 15, 1998), pp. 4646-4653.		
	A10	BELLAMY, W. et al. "Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype," <i>Cancer Chemother Pharmacol</i> (1996), Vol. 37, pp. 305-316.		
	A11	HUANG, X. et al. "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> (24 January 1997), Vol. 275, pp. 547-550.		
MB	A12	MORRISSEY, J. "Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade," <i>Cell</i> (July 3, 1987), Vol. 50, pp. 129-135, Cell Press.		

Examiner Signature	<i>Mild Kelly</i>	Date Considered	12-10-04
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: June 27, 2002

(use as many sheets as necessary)

Complete if Known

Application Number	10/089,501
Filing Date	04/22/2002
First Named Inventor	Hiroyuki SAITO et al.
Group Art Unit	Unassigned 1636
Examiner Name	Unassigned Ben K. Kline
Attorney Docket Number	053466-0325

RECEIVED
JAN 21 2003
TECH CENTER 1600199
Pages, Columns, Lines
Where Relevant

Sheet

1

of

1

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Date
Considered

12-10-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 26, 2002 (use as many sheets as necessary)			Complete if Known		
			Application Number	10/089,501	
			Filing Date	04/22/2002	
			First Named Inventor	Hiroyuki SAITO, et al.	
			Group Art Unit	Unassigned 1636	
			Examiner Name	Unassigned Burkner	
			Attorney Docket Number	053466-0325	
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MB	A1	5,346,991		ROY, et al.	09/13/1994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
MB	A2	EP	0 278 776	A2	GENENTECH, INC.	08/17/1988		
	A3	WO	88/09817	A1	MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK	12/15/1988		
MB	A4	WO	88/07543	A1	SCRIPPS CLINIC AND RESEARCH FOUNDATION	10/06/1988		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
MB	A5	DAVIE, et al., "Waterfall Sequence for Intrinsic Blood Clotting," <i>Science</i> , Vol. 145, pp. 1310-1312 (1964), USA		
	A6	GIESEN, et al., "Blood-borne tissue factor: Another view of thrombosis," <i>Proc. Natl. Acad. Sci.</i> , Vol. 96, pp. 2311-2315 (1999), Medical Sciences, USA		
	A7	TAYLOR, et al., "Lethal <i>E. coli</i> Septic Shock Is Prevented by Blocking Tissue Factor With Monoclonal Antibody," <i>Circulatory Shock</i> , Vol. 33, pp. 127-134 (1991), Wiley-Liss, Inc., USA		
	A8	MACFARLANE, "Haematology, An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier", <i>Nature</i> , Vol. 202, pp. 498-499 (1964), USA		
	A9	PAWASHE, et al., "A Monoclonal Antibody Against Rabbit Tissue Factor Inhibits Thrombus Formation in Stenotic Injured Rabbit Carotid Arteries," <i>Circulation Research</i> , Vol. 74, No. 1, pp. 56-63 (1994), USA		
MB	A10	LEVI, et al., "Inhibition of Endotoxin-induced Activation of Coagulation and Fibrinolysis by Pentoxifylline or by a Monoclonal Anti-tissue factor Antibody in Chimpanzees," <i>The Journal of Clinical Investigation, Inc.</i> , Volume 93, pp. 114-120 (1994), USA		

Examiner Signature	<i>Michael Phillips</i>	Date Considered	12-18-04
--------------------	-------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: August 23, 2002

(use as many sheets as necessary)

Complete if Known

Application Number	10/089,501
Filing Date	04/22/2002
First Named Inventor	HiroYuki SAITO, et al.
Group Art Unit	Unassigned 1676
Examiner Name	Unassigned Burkhardt
Attorney Docket Number	053466-0325

Sheet

2

of

3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MB	A11	HUANG, et al., "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> , Vol. 275, pp. 547, 550 (1997)	
	A12	HOLST, et al., "Local Application of Recombinant Active-site Inhibited Human Clotting Factor VIIa Reduces Thrombus Weight and Improves Patency in a Rabbit Venous Thrombosis Model," <i>Eur J Vasc Endovasc Surg</i> , Vol. 15, pp. 515-520 (1998), W.B. Saunders Company Ltd., USA	
	A13	BELLAMY, et al., "Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype," <i>Cancer Chemother Pharmacol</i> , Vol. 37, pp. 305-316 (1996), Springer-Verlag, Germany	
	A14	RANDOLPH, et al., "Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and Trafficking Through Endothelium In Vitro," <i>Blood</i> , Vol. 92, No. 11, pp. 4167-4177 (1998), The American Society of Hematology, USA	
	A15	HIMBER, et al., "Dissociation of Antithrombotic Effect and Bleeding Time Prolongation in Rabbits by Inhibiting Tissue Factor Function," <i>Thromb Haemost</i> , Vol. 78, pp. 1142-9 (1997), Schattauer Verlag, Germany	
	A16	RAGNI, et al., "Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis," <i>Circulation</i> , Vol. 93, No. 10, pp. 1913-1918 (1996), American Heart Association, Inc., USA	
	A17	MORRISSEY, et al., "Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade," <i>Cell</i> , Vol. 50, pp. 129-135 (1987), Cell Press, USA	
	A18	RAN, et al., "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature," <i>Cancer Research</i> , Vol. 58, pp. 4646-4653 (1998), USA	
	A19	DRAKE, et al., "Functional Tissue Factor Is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line," <i>The Journal of Cell Biology</i> , Volume 109, pp. 389-395 (1989), The Rockefeller University Press, USA	
	A20	CALLANDER, et al., "Immunohistochemical Identification of Tissue Factor in Solid Tumors," <i>Cancer</i> , Vol. 70, pp. 1194-1201 (1992), USA	
	A21	KONIGSBERG, et al., "The TF: VIIa Complex: Clinical Significance, Structure-function Relationships and Its Role in Signaling and Metastasis," <i>Thromb Haemost</i> , Vol. 86, pp. 757-771 (2001), Schattauer GmbH, Germany	
	A22	HARKER, et al., "Antithrombotic and AntileSION Benefits without Hemorrhagic Risks by Inhibiting Tissue Factor Pathway," <i>Haemostasis</i> , Vol. 26, pp. 76-82 (1996), S. Karger AG, Switzerland	
	A23	HOUGIE, "Reactions of Stuart Factor and Factor VII with Brain and Factor V," <i>P.S.E.B.M.</i> , Vol. 101, pp. 132-135 (1959), National Heart Institute, USA	
MB	A24	NAKAYAMA, et al., "Anticoagulation Therapy by Inhibiting Extrinsic Pathway", <i>TRANSLATION OF Hematology & Oncology</i> , Vol. 39, No. 4, pp. 298-302 (1999), First Department of Internal Medicine, Nagoya University School of Medicine, Japan	

Examiner
Signature

Michael H. H. S.

Date
Considered

12-10-09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 23, 2002 (use as many sheets as necessary)		Application Number	10/089,501
		Filing Date	04/22/2002
		First Named Inventor	HiroYuki SAITO, et al.
		Group Art Unit	Unassigned 1136
		Examiner Name	Unassigned M. Burkhardt
Sheet	3	of	3
		Attorney Docket Number	053466-0325

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner Signature	<i>and Kles</i>	Date Considered	12-10-04
-----------------------	-----------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.